Biotech company 10x Genomics (NASDAQ: TXG) will be reporting results this Thursday after market hours. Here’s what to expect.
10x Genomics beat analysts’ revenue expectations by 16.7% last quarter, reporting revenues of $154.9 million, up 9.8% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ EPS estimates and revenue guidance for next quarter meeting analysts’ expectations.
Is 10x Genomics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting 10x Genomics’s revenue to decline 8.9% year on year to $139.5 million, a reversal from the 4.3% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.08 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. 10x Genomics has missed Wall Street’s revenue estimates twice over the last two years.
Looking at 10x Genomics’s peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Illumina’s revenues decreased 3% year on year, beating analysts’ expectations by 1%, and West Pharmaceutical Services reported revenues up 9.2%, topping estimates by 5.6%. Illumina traded down 8% following the results while West Pharmaceutical Services was up 15.9%.
Read our full analysis of Illumina’s results here and West Pharmaceutical Services’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. 10x Genomics is up 11.7% during the same time and is heading into earnings with an average analyst price target of $13.54 (compared to the current share price of $13.31).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
